A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer Journal Article
| Authors: | Sharma, S.; Qian, F.; Keitz, B.; Driscoll, D.; Scanlan, M. J.; Skipper, J.; Rodabaugh, K.; Lele, S.; Old, L. J.; Odunsi, K. |
| Article Title: | A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer |
| Abstract: | Objectives. Cancer-testis (CT) antigens are expressed in tumors but not normal tissues except the testis and could be targets for vaccine therapy in epithelial ovarian cancer (EOC). A-kinase anchoring protein 3 (AKAP-3) is a novel member of the CT antigen family. The aim of this study was to examine the expression of AKAP-3 in EOC and correlate with clinico-pathologic characteristics. Methods. One step RT-PCR was performed with RNA from normal and ovarian cancer cell lines and 74 epithelial ovarian tumor tissues. AKAP-3-specific PCR product was amplified. The distribution of AKAP-3 expression and clinico-pathologic variables was analyzed. Survival distributions were estimated, and multivariate analyses were performed. Results. AKAP-3 mRNA expression was demonstrated in 43/74 (58%) of the ovarian cancer specimens. AKAP-3 was expressed in normal testis, but not in other normal tissues. AKAP-3 expression significantly correlated with increased likelihood of residual tumor (P = 0.005), but no increase in the likelihood of recurrence or persistent disease (P = 0.06). Patients with AKAP-3 mRNA expression were found to have a significantly poorer overall survival (median 50 months) compared with patients without AKAP-3 expression (median not reached) (P = 0.007). Multivariate analysis of AKAP-3 expression, residual disease, and response to frontline chemotherapy found response to be the strongest predictor of overall survival (P = 0.012). Conclusions. Our data demonstrate that AKAP-3 is expressed at high frequency in patients with EOC. Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC. © 2005 Elsevier Inc. All rights reserved. |
| Keywords: | adult; cancer survival; controlled study; aged; aged, 80 and over; middle aged; survival rate; human cell; clinical feature; cancer recurrence; conference paper; neoplasm staging; polymerase chain reaction; ovarian cancer; ovarian neoplasms; cell survival; reverse transcription polymerase chain reaction; ovary cancer; gene amplification; gene expression; analytic method; correlation analysis; statistical significance; immunotherapy; rna, messenger; adaptor proteins, signal transducing; epithelial cells; epithelium; clinical examination; cancer-testis antigen; cyclic amp dependent protein kinase anchoring protein; akap-3 |
| Journal Title: | Gynecologic Oncology |
| Volume: | 99 |
| Issue: | 1 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2005-10-01 |
| Start Page: | 183 |
| End Page: | 188 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2005.06.006 |
| PUBMED: | 16005946 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 9" - "Export Date: 24 October 2012" - "CODEN: GYNOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work